Jena | Jotup

EQS-News: Intershop Communications AG expands Management Board

Retrieved on:

星期四, 十二月 7, 2023

Commerce, Deutsche Telekom, Jena, Intershop Communications AG, ISIN, CFO, Supervisory board, West Coast of Vancouver Island Aquatic Management Board, Vernier Software & Technology, Software, Software as a service, Haufe HA-G-1 Buggie, Management

Jena, 21 November 2023 – Intershop Communications AG (ISIN: DE000A254211), a global provider of B2B commerce solutions for the upper mid-market in the manufacturing and wholesale sectors, announces the upcoming expansion of its Management Board.

Key Points:

Jena, 21 November 2023 – Intershop Communications AG (ISIN: DE000A254211), a global provider of B2B commerce solutions for the upper mid-market in the manufacturing and wholesale sectors, announces the upcoming expansion of its Management Board.
As of 1 December 2023, Markus Dränert will join the Intershop Management Board as Chief Operations Officer alongside Markus Klahn (CEO) and Petra Stappenbeck (CFO).
As COO, Markus Dränert will drive the further development of Intershop’s cloud offerings and the implementation of its AI strategy.
“We are delighted to have gained such an innovative manager as Markus Dränert,” said Frank Fischer, Chairman of the Supervisory Board of Intershop Communications AG.

Porosome Therapeutics Announces Groundbreaking Approach to Advance Diabetes Treatment

Retrieved on:

星期一, 十月 30, 2023

Porosome Therapeutics, Inc. (Porosome Therapeutics) has announced a new and distinctive therapy for Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) targeting the insulin secretory defects founds in beta cells associated with the disease.

Key Points:

Porosome Therapeutics, Inc. (Porosome Therapeutics) has announced a new and distinctive therapy for Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) targeting the insulin secretory defects founds in beta cells associated with the disease.
Porosome Therapeutics’ approach addresses the cell's secretory machinery.
Porosome Therapeutics Founder and Chairman Professor Bhanu P. Jena discovered a new cellular structure called the porosome nearly three decades ago.
“These groundbreaking developments to treat diabetes directly address insulin secretion in cells and provide tremendous promise for people with diabetes,” said Guillermo Marmol, CEO, Porosome Therapeutics.

EQS-News: Intershop publishes figures for the first nine months of 2023

Retrieved on:

星期四, 十月 26, 2023

Cloud, ARR, Tax, ISIN, EBITDA, Intershop, Jena, Intershop Communications AG, Maintenance, EBIT, Growth, Marketing, EUR, Depreciation, Commerce, Film industry, Lithium

Revenues from the strategically important cloud business rose by 14% to EUR 11.8 million (previous year: EUR 10.4 million).

Key Points:

Revenues from the strategically important cloud business rose by 14% to EUR 11.8 million (previous year: EUR 10.4 million).
Service revenues again showed a positive trend, rising by 9% to EUR 10.5 million in the first nine months of 2023 (previous year: EUR 9.6 million).
Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 1.1 million in the first nine months of 2023 (previous year: EUR 1.3 million).
For the full year 2023, Intershop projects slight revenue growth, negative but improved EBIT (previous year: EUR -2.9 million), incoming cloud orders of between EUR 24.0 million and EUR 26.0 million (previous year: EUR 25.9 million), and net new ARR of between EUR 1.5 million and EUR 2.5 million (previous year: EUR 3.2 million).

Daily Racing Form Congratulates Brand Ambassador Jena Antonucci, Trainer of Travers Stakes Winner

Retrieved on:

星期二, 八月 29, 2023

Professional Services, Equestrian, Sports, Finance, Partnership, Travers, Forte, Multimedia, Travers Stakes, Arcangelo, Mage, Triple Crown, Sport, Belmont Stakes, Jena, DRF, Female, Entertainment

Daily Racing Form (“DRF”), a leading provider of premium data and authoritative editorial coverage to sports and horse racing enthusiasts in North America, today joined the horse racing community in continuing to celebrate the victory by Arcangelo and trainer Jena Antonucci, a DRF Brand Ambassador, in Saturday’s Grade 1, $1.25 million Travers Stakes at Saratoga.

Key Points:

Daily Racing Form (“DRF”), a leading provider of premium data and authoritative editorial coverage to sports and horse racing enthusiasts in North America, today joined the horse racing community in continuing to celebrate the victory by Arcangelo and trainer Jena Antonucci, a DRF Brand Ambassador, in Saturday’s Grade 1, $1.25 million Travers Stakes at Saratoga.
She is the second female trainer to win the Travers, following Thanksgiving’s win with Mary Hirsch in 1938.
“The DRF family congratulates Jena Antonucci and her team," said Scott Butera, Chief Executive Officer of Sports Information Group, the publisher of DRF.
“We look forward to more victories and a continued, fruitful partnership between Jena and DRF.”
For more information about the DRF and Jena Antonucci partnership, please visit:

EQS-News: Intershop publishes figures for the first half of 2023

Retrieved on:

星期三, 七月 26, 2023

Cloud, Maintenance, Marketing, Intershop Communications AG, Tax, EBIT, B2C, EUR, EBITDA, ARR, Commerce, Intershop, ISIN, Depreciation, Growth, Jena, Film industry, Lithium

Revenues from the strategically important cloud business rose by 16% to EUR 7.8 million (previous year: EUR 6.7 million).

Key Points:

Revenues from the strategically important cloud business rose by 16% to EUR 7.8 million (previous year: EUR 6.7 million).
Cloud ARR (annual recurring revenues) rose to EUR 16.1 million as of 30 June 2023 – an increase of 12% (previous year: EUR 14.4 million).
Cash and cash equivalents amounted to EUR 10.1 million as at 30 June 2023 (31 December 2022: EUR 10.5 million).
Moreover, Intershop expects incoming cloud orders worth between EUR 24.0 million and EUR 26.0 million (previous year: EUR 25.9 million) and net new ARR of between EUR 1.5 million and EUR 2.5 million (previous year: EUR 3.2 million).

EQS-News: Intershop Shareholders’ Meeting: Management Board looks back on the past financial year and presents future trends in B2B commerce

Retrieved on:

星期二, 五月 9, 2023

Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Intershop Communications AG, Supervisory board, Intelligence, AGM, Acquisition, Guideline, Commerce, Intershop, ISIN, CFO, Artificial intelligence, AI, Jena, Security (finance), Management

Shareholders were also given the possibility to attend the Shareholders’ Meeting live on the company’s AGM portal.

Key Points:

Shareholders were also given the possibility to attend the Shareholders’ Meeting live on the company’s AGM portal.
After an introduction, Markus Klahn presented the development path in B2B e-commerce, which also serves as a guideline for Intershop.
“Autonomous commerce is one of the most exciting trends in B2B commerce.
After a cautious start to the current financial year, the Management Board is optimistic about the coming quarters.

EQS-News: Intershop continues to grow its cloud business in 2022

Retrieved on:

星期三, 二月 22, 2023

Intershop continued to accelerate its growth to expand the cloud business in the reporting period.

Key Points:

Intershop continued to accelerate its growth to expand the cloud business in the reporting period.
Realized cloud revenues rose by 28% to EUR 14.2 million in the past financial year (2021: EUR 11.1 million).
Incoming cloud orders picked up by 42% to EUR 25.9 million, while net new ARR increased by 14% to EUR 3.2 million.
Annual recurring revenues (ARR) were up by 27% to EUR 15.4 million as of 31 December 2022 (31 December 2021: EUR 12.2 million).

EQS-News: Intershop publishes figures for the first nine months of 2022

Retrieved on:

星期五, 十月 28, 2022

Revenues from the strategically focused cloud business rose by 27% to EUR 10.4 million (previous year: EUR 8.1 million).

Key Points:

Revenues from the strategically focused cloud business rose by 27% to EUR 10.4 million (previous year: EUR 8.1 million).
Incoming cloud orders climbed 65% to EUR 18.7 million, thus exceeding the level of the full previous year after only nine months.
Cloud ARR (annual recurring revenues) rose to EUR 15.1 million as of 30 September 2022 an increase of 32% (previous year: EUR 11.4 million).
Earnings before interest and taxes (EBIT) stood at EUR -1.1 million at the nine-month stage of 2022 (previous year: EUR 1.2 million).

DGAP-News: Intershop Management Board gives Shareholders’ Meeting deeper insight into corporate and product strategy – Supervisory Board expanded to four members

Retrieved on:

星期二, 五月 10, 2022

Jena, 10 May 2022 Intershop Communications AG (ISIN: DE000A254211), a global provider of B2B commerce solutions for the upper mid-market and wholesalers, today held its Annual Shareholders Meeting.

Key Points:

Jena, 10 May 2022 Intershop Communications AG (ISIN: DE000A254211), a global provider of B2B commerce solutions for the upper mid-market and wholesalers, today held its Annual Shareholders Meeting.
As in the previous year, the Shareholders Meeting was held virtually, without the shareholders being physically present.
The other members of the Supervisory Board were re-elected at the Shareholders Meeting for a further five years.
The managements resolution proposals for all items on the agenda were approved by a large majority of the shareholders.

InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

Retrieved on:

星期一, 十一月 15, 2021

The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to standard of care, while significantly reducing the need for glucocorticoid (GC) treatment in this life-threatening indication.

Key Points:

The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to standard of care, while significantly reducing the need for glucocorticoid (GC) treatment in this life-threatening indication.
Vilobelimab treatment led to a considerably reduced use of glucocorticoids, resulting in remarkably less treatment emergent adverse events and a reduction in the glucocorticoid toxicity index.
The randomized, double-blind, placebo-controlled, two-part, Phase II IXCHANGE study enrolled 57 patients (30 in part 1; 27 in part 2) with AAV throughout Europe.
The study was not statistically powered to demonstrate non-inferiority of vilobelimab alone compared to a standard dose of GC therapy.